Results from the survey
Availability of double combination Tenofovir+Lamivudine has grown from complete unavailability in 2011 to 62% of facilities in this survey. At the same, results show that the highly toxic combination of Lamivudine+ Nevarapine + Stavudine (commonly known as Triomune) has phased out completely as it was not found at any treatment site.
Availability of medicines for children remains was very poor. The only triple combination medicine available Lamivudine+Nevirapine+Stavudine was in less than 3% of public facilities; in none of the private facilities; and only 8% of mission facilities.